precancerous lesions
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
p53 tumor suppressor gene mutation in early esophageal precancerous lesions and carcinoma among high-risk populations in Henan, China.
|
8044781 |
1994 |
precancerous lesions
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Analysis of nuclear DNA content and p53 immunostaining appears to be useful as an adjunct to histopathology in the evaluation of true precancerous lesions.
|
8864734 |
1997 |
precancerous lesions
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
By means of CDKN2A and p53 mutation screening (single-strand conformational polymorphism analysis and sequencing), methylation analysis of alternative CDKN2A promoters (methylation-specific polymerase chain reaction) and p53 immununochemistry, we analysed eight invasive EGCs (five from vulva and three from penis) and 25 precancerous lesions (two undifferentiated VIN3 and 23 vulval/penile lesions of LS) from 33 patients.
|
17300232 |
2007 |
precancerous lesions
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Deletion of Nrf2 in KPC mice (KPCN) decreased the formation of precancerous lesions as well as the development of invasive pancreatic cancer.
|
29240881 |
2017 |
precancerous lesions
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Discordant p53 alterations, such as those seen in cancerous and isolated precancerous lesions, may thus demonstrate further evidence for a multicentric or field carcinogenesis of the human oesophagus.
|
10993651 |
2000 |
precancerous lesions
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Expression and clinical implications of enhancer of Zeste homolog 2 and p53 protein in squamous cell carcinoma and precancerous lesions in the cervix.
|
27323178 |
2016 |
precancerous lesions
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Furthermore, they behaved as early markers of epithelial transformation because they were present in sera of patients with early-stage tumors and precancerous lesions such as colorectal polyps and in sera of patients that were scored negative for other cancer serological markers (CEA, CA15-3, CA19-9, p53 antibodies).
|
11245444 |
2001 |
precancerous lesions
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Genomic instability in precancerous lesions before inactivation of tumor suppressors p53 and APC in patients.
|
16855398 |
2006 |
precancerous lesions
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Immunohistochemical staining p53 analysis and ICM DNA analysis does increase the diagnostic sensitivity for cancerous and true precancerous lesions in the larynx.
|
9059867 |
1997 |
precancerous lesions
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Immunohistoselective sequencing (IHSS) of p53 tumor suppressor gene in human oesophageal precancerous lesions.
|
8895479 |
1996 |
precancerous lesions
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
In addition, TUNEL staining was used to evaluate apoptosis, and we further used immunohistochemically labelled CDX2, MUC2, ki-67, PTEN, and p53 proteins to assess the characteristic changes of gastric mucosa in precancerous lesions.
|
31744486 |
2019 |
precancerous lesions
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
In order to develop useful diagnosis of pre-malignant lesions, expression of p53 family members and the cancer stem cell (CSCs) marker, CD44v6, were studied in histologically normal oral epithelium, precancerous lesions and succeeding invasive OSCCs. p53 was expressed focally in normal epithelium adjacent to tumors, while expression was high in intra-epithelial neoplasia and moderate in OSCC. p63 nuclear staining was important in basal and suprabasal layers of histologically normal oral mucosa and in immature compartments of premalignant lesions and cancer.
|
20054805 |
2010 |
precancerous lesions
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
In SCC development, UV-signature mutations in the p53 tumor suppressor gene are the most common event, as precancerous lesions reveal -80% and SCCs > 90% UV-specific p53 mutations.
|
25207368 |
2014 |
precancerous lesions
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
It has been frequently shown that p53 alterations have an important role in the development of gastric cancers but there is no data on p53 alteration in gastric cancer and its precancerous lesions from Iran although this country experiences one of the highest gastric cancer incidence and mortality rates in the world.
|
21042017 |
2011 |
precancerous lesions
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Microdissection would increase the detection rate of the p53 gene mutations and LOH not only in skin cancer but also in precancerous lesions.
|
10940505 |
2000 |
precancerous lesions
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
No mutation of p53 gene was detected in any samples of the control and three precancerous lesions of the tongue.
|
9769393 |
1998 |
precancerous lesions
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Our results indicate that p53 overexpression is an early event in oral carcinogenesis never influencing the proliferative advantage in oral precancerous lesions.
|
9261738 |
1997 |
precancerous lesions
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
p53 and p21 expression in precancerous lesions and carcinomas of the uterine cervix: overexpression of p53 predicts poor disease outcome.
|
11606096 |
2001 |
precancerous lesions
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
PRb2/p130, p107 and p53 expression in precancerous lesions and squamous cell carcinoma of the uterine cervix.
|
16158962 |
2005 |
precancerous lesions
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
The aim of this study was to evaluate the status of p53 overexpression and human papillomavirus (HPV) infection in patients with precancerous lesions of the vulva.
|
9445189 |
1998 |
precancerous lesions
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
The data indicate that the loss of Fhit protein is the most frequent alteration in non-small cell lung cancer (73%) and precancerous lesions (93%), is significantly higher in the tumors of smokers (75%) than in those of nonsmokers (39%; P < 0.0005), and is an independent and more frequent event than p53 overexpression in tumors and precancerous lesions (73 versus 46%).
|
9823304 |
1998 |
precancerous lesions
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The different histological forms of both esophageal and gastric carcinomas as well as their differing etiologies result in the possibility that a spectrum of genetic changes is involved in different tumor types. p53 abnormalities occur frequently in tumors arising in both organs, and in both sites p53 abnormalities can be observed in precancerous lesions as well as in overt cancer.
|
7927320 |
1994 |
precancerous lesions
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
The diverse patterns of p53 mutation among HGPIN and PCA lesions suggested multiclonal development of prostatic precancerous lesions.
|
9800953 |
1998 |
precancerous lesions
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
The purpose of this study was to investigate the incidence of MDM2 and its relationship to the expression of p53 in oral squamous cell carcinoma and precancerous lesions.
|
8692535 |
1996 |
precancerous lesions
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
These findings indicate that p53 gene mutation is an early event and occurs frequently at an early stage of precancerous lesions and may be responsible for most cases of malignant transformation of PA.
|
9648154 |
1998 |